FOLD
Amicus Therapeutics, Inc.
Biotechnology
Market Cap$4.47B
5Y Perf.+16.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
FOLD vs BMRN
Revenue, margins, valuation, and 5-year total return — side by side.
BMRN
BioMarin Pharmaceutical Inc.
Biotechnology
Market Cap$10.50B
5Y Perf.-47.0%
FOLD vs BMRN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | FOLD | BMRN |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $4.47B | $10.50B |
| Revenue (TTM) | $599M | $3.24B |
| Net Income (TTM) | $-14M | $269M |
| Gross Margin | 89.5% | 75.9% |
| Operating Margin | 5.5% | 13.8% |
| Forward P/E | 40.6x | 12.7x |
| Total Debt | $444M | $643M |
| Cash & Equiv. | $214M | $1.31B |
FOLD vs BMRN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
FOLD
BMRN
| Stock | May 20 | Apr 26 | Return |
|---|---|---|---|
| Amicus Therapeutics… (FOLD) | 100 | 116.2 | +16.2% |
| BioMarin Pharmaceut… (BMRN) | 100 | 53.0 | -47.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: FOLD vs BMRN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: FOLD and BMRN are tied at the top with 3 categories each — the right choice depends on your priorities. BioMarin Pharmaceutical Inc. is the stronger pick specifically for valuation and capital efficiency and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
FOLD
Amicus Therapeutics, Inc.
The Income Pick
FOLD has the current edge in this matchup, primarily because of its strength in income & stability and growth exposure.
- beta 0.63
- Rev growth 32.3%, EPS growth 64.7%, 3Y rev CAGR 20.0%
- 125.0% 10Y total return vs BMRN's -32.4%
Best for: income & stability and growth exposure
BMRN
BioMarin Pharmaceutical Inc.
The Value Play
BMRN is the clearest fit if your priority is value and quality.
- Lower P/E (12.7x vs 40.6x)
- 8.3% margin vs FOLD's -2.3%
- 3.4% ROA vs FOLD's -1.6%, ROIC 7.4% vs 4.8%
Best for: value and quality
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | FOLD | 32.3% revenue growth vs BMRN's 12.9% |
| Value | BMRN | Lower P/E (12.7x vs 40.6x) |
| Quality / Margins | BMRN | 8.3% margin vs FOLD's -2.3% |
| Stability / Safety | FOLD | Beta 0.63 vs BMRN's 0.65 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | FOLD | +134.1% vs BMRN's -8.5% |
| Efficiency (ROA) | BMRN | 3.4% ROA vs FOLD's -1.6%, ROIC 7.4% vs 4.8% |
FOLD vs BMRN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
FOLD vs BMRN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLFOLDLAGGINGBMRN
BMRNBioMarin Pharmaceutic…
2leads
FOLDAmicus Therapeutics, …
2leads
6 Total Categories
CATEGORYLEADERvs BMRNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
BMRN4/5
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
BMRN7/8
Total Returns1Y, 3Y, 5Y total returns with dividends
FOLD6/6
Risk & VolatilityBeta, volatility, and downside exposure
FOLD2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — FOLD and BMRN each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
BMRN is the larger business by revenue, generating $3.2B annually — 5.4x FOLD's $599M. BMRN is the more profitable business, keeping 8.3% of every revenue dollar as net income compared to FOLD's -2.3%. On growth, FOLD holds the edge at +19.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | FOLDAmicus Therapeuti… | BMRNBioMarin Pharmace… |
|---|---|---|
| RevenueTrailing 12 months | $599M | $3.2B |
| EBITDAEarnings before interest/tax | $40M | $521M |
| Net IncomeAfter-tax profit | -$14M | $269M |
| Free Cash FlowCash after capex | $10M | $767M |
| Gross MarginGross profit ÷ Revenue | +89.5% | +75.9% |
| Operating MarginEBIT ÷ Revenue | +5.5% | +13.8% |
| Net MarginNet income ÷ Revenue | -2.3% | +8.3% |
| FCF MarginFCF ÷ Revenue | +1.6% | +23.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +19.5% | +2.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +3.8% | -43.2% |
Evenly matched — FOLD and BMRN each lead in 3 of 6 comparable metrics.
Valuation Metrics
BMRN leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
On an enterprise value basis, BMRN's 16.0x EV/EBITDA is more attractive than FOLD's 140.6x.
| Metric | FOLDAmicus Therapeuti… | BMRNBioMarin Pharmace… |
|---|---|---|
| Market CapShares × price | $4.5B | $10.5B |
| Enterprise ValueMkt cap + debt − cash | $4.7B | $9.8B |
| Trailing P/EPrice ÷ TTM EPS | -80.50x | 30.33x |
| Forward P/EPrice ÷ next-FY EPS est. | 40.62x | 12.71x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 140.62x | 16.04x |
| Price / SalesMarket cap ÷ Revenue | 8.46x | 3.26x |
| Price / BookPrice ÷ Book value/share | 22.73x | 1.77x |
| Price / FCFMarket cap ÷ FCF | — | 14.48x |
BMRN leads this category, winning 4 of 5 comparable metrics.
Profitability & Efficiency
BMRN leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
BMRN delivers a 4.4% return on equity — every $100 of shareholder capital generates $4 in annual profit, vs $-6 for FOLD. BMRN carries lower financial leverage with a 0.11x debt-to-equity ratio, signaling a more conservative balance sheet compared to FOLD's 2.29x.
| Metric | FOLDAmicus Therapeuti… | BMRNBioMarin Pharmace… |
|---|---|---|
| ROE (TTM)Return on equity | -6.1% | +4.4% |
| ROA (TTM)Return on assets | -1.6% | +3.4% |
| ROICReturn on invested capital | +4.8% | +7.4% |
| ROCEReturn on capital employed | +4.0% | +8.1% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 |
| Debt / EquityFinancial leverage | 2.29x | 0.11x |
| Net DebtTotal debt minus cash | $230M | -$669M |
| Cash & Equiv.Liquid assets | $214M | $1.3B |
| Total DebtShort + long-term debt | $444M | $643M |
| Interest CoverageEBIT ÷ Interest expense | 1.11x | 16.96x |
BMRN leads this category, winning 7 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
FOLD leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in FOLD five years ago would be worth $15,094 today (with dividends reinvested), compared to $6,946 for BMRN. Over the past 12 months, FOLD leads with a +134.1% total return vs BMRN's -8.5%. The 3-year compound annual growth rate (CAGR) favors FOLD at 6.0% vs BMRN's -17.1% — a key indicator of consistent wealth creation.
| Metric | FOLDAmicus Therapeuti… | BMRNBioMarin Pharmace… |
|---|---|---|
| YTD ReturnYear-to-date | +1.5% | -8.2% |
| 1-Year ReturnPast 12 months | +134.1% | -8.5% |
| 3-Year ReturnCumulative with dividends | +19.0% | -43.1% |
| 5-Year ReturnCumulative with dividends | +50.9% | -30.5% |
| 10-Year ReturnCumulative with dividends | +125.0% | -32.4% |
| CAGR (3Y)Annualised 3-year return | +6.0% | -17.1% |
FOLD leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
FOLD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
FOLD is the less volatile stock with a 0.63 beta — it tends to amplify market swings less than BMRN's 0.65 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FOLD currently trades 99.9% from its 52-week high vs BMRN's 82.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | FOLDAmicus Therapeuti… | BMRNBioMarin Pharmace… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.63x | 0.65x |
| 52-Week HighHighest price in past year | $14.50 | $66.28 |
| 52-Week LowLowest price in past year | $5.51 | $50.76 |
| % of 52W HighCurrent price vs 52-week peak | +99.9% | +82.4% |
| RSI (14)Momentum oscillator 0–100 | 72.2 | 41.9 |
| Avg Volume (50D)Average daily shares traded | 3.0M | 1.8M |
FOLD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates FOLD as "Buy" and BMRN as "Buy". Consensus price targets imply 64.2% upside for BMRN (target: $90) vs 0.1% for FOLD (target: $15).
| Metric | FOLDAmicus Therapeuti… | BMRNBioMarin Pharmace… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $14.50 | $89.64 |
| # AnalystsCovering analysts | 24 | 41 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
BMRN leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). FOLD leads in 2 (Total Returns, Risk & Volatility). 1 tied.
Best OverallAmicus Therapeutics, Inc. (FOLD)Leads 2 of 6 categories
Loading custom metrics...
FOLD vs BMRN: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is FOLD or BMRN a better buy right now?
For growth investors, Amicus Therapeutics, Inc.
(FOLD) is the stronger pick with 32. 3% revenue growth year-over-year, versus 12. 9% for BioMarin Pharmaceutical Inc. (BMRN). BioMarin Pharmaceutical Inc. (BMRN) offers the better valuation at 30. 3x trailing P/E (12. 7x forward), making it the more compelling value choice. Analysts rate Amicus Therapeutics, Inc. (FOLD) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — FOLD or BMRN?
On forward P/E, BioMarin Pharmaceutical Inc.
is actually cheaper at 12. 7x.
03Which is the better long-term investment — FOLD or BMRN?
Over the past 5 years, Amicus Therapeutics, Inc.
(FOLD) delivered a total return of +50. 9%, compared to -30. 5% for BioMarin Pharmaceutical Inc. (BMRN). Over 10 years, the gap is even starker: FOLD returned +125. 0% versus BMRN's -32. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — FOLD or BMRN?
By beta (market sensitivity over 5 years), Amicus Therapeutics, Inc.
(FOLD) is the lower-risk stock at 0. 63β versus BioMarin Pharmaceutical Inc. 's 0. 65β — meaning BMRN is approximately 3% more volatile than FOLD relative to the S&P 500. On balance sheet safety, BioMarin Pharmaceutical Inc. (BMRN) carries a lower debt/equity ratio of 11% versus 2% for Amicus Therapeutics, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — FOLD or BMRN?
By revenue growth (latest reported year), Amicus Therapeutics, Inc.
(FOLD) is pulling ahead at 32. 3% versus 12. 9% for BioMarin Pharmaceutical Inc. (BMRN). On earnings-per-share growth, the picture is similar: Amicus Therapeutics, Inc. grew EPS 64. 7% year-over-year, compared to -18. 6% for BioMarin Pharmaceutical Inc.. Over a 3-year CAGR, FOLD leads at 20. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — FOLD or BMRN?
BioMarin Pharmaceutical Inc.
(BMRN) is the more profitable company, earning 10. 8% net margin versus -10. 6% for Amicus Therapeutics, Inc. — meaning it keeps 10. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BMRN leads at 16. 6% versus 4. 7% for FOLD. At the gross margin level — before operating expenses — FOLD leads at 90. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is FOLD or BMRN more undervalued right now?
On forward earnings alone, BioMarin Pharmaceutical Inc.
(BMRN) trades at 12. 7x forward P/E versus 40. 6x for Amicus Therapeutics, Inc. — 27. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BMRN: 64. 2% to $89. 64.
08Which pays a better dividend — FOLD or BMRN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is FOLD or BMRN better for a retirement portfolio?
For long-horizon retirement investors, Amicus Therapeutics, Inc.
(FOLD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 63), +125. 0% 10Y return). Both have compounded well over 10 years (FOLD: +125. 0%, BMRN: -32. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between FOLD and BMRN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: FOLD is a small-cap high-growth stock; BMRN is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(FOLD: 19.5% · BMRN: 2.8%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.